Introduction
============

For both males and females, lung cancer is the most common malignant tumor (11.6% of general cases) and the leading cause of cancer deaths (accounting for 18.4% of cancer deaths) ([@ref-5]). Approximately 85% of patients with non-small cell lung cancer are diagnosed with lung squamous cell carcinoma (LUSC), which is the major subtype of non-small cell lung cancer ([@ref-38]). Unlike other cancers, due to the lack of clear histological features ([@ref-12]), there are no specific individualized treatment strategies for conventional radiotherapy, chemotherapy or targeted therapy of LUSC, although some treatments are clinically effective ([@ref-14]; [@ref-30]). This situation is due in large part to the limited knowledge of the molecular mechanisms of LUSC in existing studies ([@ref-11]; [@ref-9]; [@ref-20]). Therefore, identifying potential prognostic markers is critical to improving the efficiency of LUSC treatment and ameliorating its prognosis.

Long noncoding RNAs (lncRNAs) are non-coding RNAs greater than 200 nucleotides in length. Studies have shown that lncRNAs play an important role in many biological processes such as the dose compensation effect as well as epigenetic, cell cycle and cell differentiation regulation, and has become a hot research topic in genetics ([@ref-25]). With the development of high-throughput sequencing and RNA analysis technology, the possible role of lncRNA in cancer is being comprehensively studied ([@ref-45]; [@ref-50]). A growing body of research has shown that lncRNAs play a role in the formation, development and prognosis of a variety of cancers ([@ref-43]), including prostate cancer ([@ref-51]), hepatocellular carcinoma ([@ref-48]), gastric cancer ([@ref-39]), and lung cancer ([@ref-36]); what's more, the concept of competitive endogenous RNA (ceRNA) has revealed a new mechanism for interaction between RNAs which has broadened our understanding of lncRNA function ([@ref-35]). The regulation of lncRNAs in ceRNA networks has been partially confirmed by related studies ([@ref-24]), but there has been few research on LUSC.

Therefore, our work aims to identify potential prognosis lncRNAs for LUSC. The Cancer Genome Atlas (TCGA) database provides multidimensional information for cancer research. In our study, sequence data and clinical information on lncRNA, microRNA (miRNA) and mRNA in samples from LUSC patients was retrieved from the TCGA database, and the lncRNA-miRNA-mRNA ceRNA network was constructed. In order to improve the reliability of our research, we used data from the Gene Expression Omnibus (GEO) database to confirm the results. In present study, the specific lncRNAs identified based on ceRNA network will provide a new theoretical basis for the prognosis and targeted therapy of LUSC patients.

Materials and Methods
=====================

Collection of relevant data from the TCGA database
--------------------------------------------------

We selected the TCGA database (<https://cancergenome.nih.gov/>) to gather LUSC-related RNA sequencing (RNA-Seq) data and clinical information. The RNA-seq data includes three types of RNA, lncRNA, miRNA and mRNA. And the exclusion criteria were as follows (1) two or more malignant tumors coexist in same sample, and (2) the sample was deficient in clinical information. After culling, samples with complete clinical information and gene expression matrices were included in this study.

Data preprocessing and differential analysis of genes
-----------------------------------------------------

In order to improve the reliability of the analytical data, we filtered the raw data retrieved from TCGA database and standardized the RNA-Seq (including lncRNA, miRNA and mRNA) and clinical data by the trimmed mean of *M*-values method. The filter criteria are set to ensure that (1) at least 25% of the sample is removed, and (2) the expression value of the gene is greater than 2. Then, the edgeR R software package was used to identify differentially expressed lncRNAs (DElncRNA), miRNAs (DEmiRNA) and mRNAs (DEmRNA) in the RNA matrix and FDR, \|logFC\| and *P*-values were calculated. The limit of value is that FDR \< 0.01, \|logFC\| \> 1 and *P*-value \< 0.01. The R software packages ggplot2 was used to create volcano plots and heatmaps respectively in order to visualize the results of the differential genetic analysis.

Construction of the ceRNA network
---------------------------------

Competitive endogenous RNAs can bind to miRNAs through miRNA response elements (MREs), which affects the expression of genes regulated by miRNAs ([@ref-2]; [@ref-31]). What's more, lncRNAs compete with each other to interact with miRNAs making them ceRNAs ([@ref-17]). Given this theoretical basis, we constructed a ceRNA network for lncRNA-miRNA-mRNA interactions using the following steps: (1) differentially expressed RNAs (DElncRNA, DEmiRNA, DEmRNA) with a FDR \< 0.01, \|logFC\| \> 1 and *P*-value \< 0.01 were retained, and (2) the online tool, miRcode (<http://www.mirdb.org/>), was applied to predict the interaction and regulation relationships between the lncRNAs and miRNAs, and (3) two online sites, StarBase (<http://starbase.sysu.edu.cn>), TargetScanHuman (<http://www.targetscan.org>), were used to predict target genes for the miRNAs. Next, the results of the intersecting genes were determined using a Venn diagram. After comparison and prediction, we identified a certain number of lncRNAs, miRNAs and mRNAs and the relationship between the three of them. The ceRNA network map was finally obtained by visualizing the three types of RNAs and their interactions using Cytoscape (version 3.6.1).

Gene ontology enrichment analysis
---------------------------------

Through the Gene ontology (GO) annotations of differentially expressed genes, GO classification entries enriched with differential genes can be found, and it is possible to find differential genes in different samples which may be related to changes in gene function ([@ref-3]). There is a link between lncRNA and its corresponding mRNA in terms of potential biological function. Therefore, we performed GO functional enrichment analysis on DEmRNAs in the ceRNA network using DAVID (an online functional annotation tool, <https://david.ncifcrf.gov/>) terms with a *P*-value \< 0.05 were considered significant in biological processes. In addition, we performed GO enrichment analysis on all 417 DEmRNAs and compared GO terms between all 417 DEmRNAs and 11 mRNAs.

Verification of prognosis-related RNAs and construction of prognostic model
---------------------------------------------------------------------------

We utilized the survival package to generate Kaplan--Meier separate survival analysis and log-rank tests for the DElncRNAs and DEmiRNAs in the ceRNA network to correlate them with overall survival of LUSC patients, a *P*-value \< 0.05 was considered statistically significant. Datasets ([GSE8569](GSE8569), [GSE21933](GSE21933), [GSE33479](GSE33479), [GSE40275](GSE40275)) from the GEO database (<https://www.ncbi.nlm.nih.gov/gds/>) were used to validate the correlation of DEmRNAs in the ceRNA network with survival. In addition, we used univariate Cox analysis to assess the risk score and overall survival correlation of the DElncRNAs, which was followed by multivariate Cox analysis to establish the lncRNAs prognostic model of LUSC.
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}{}$$\eqalign{{\rm{Risk}}\;{\rm{score}} & = {\rm{exp}}\;{\rm{ln}}\;{\rm{cRNA1}}\times \beta {\rm{ln}}\;{\rm{cRNA1}} + {\rm{exp}}\;{\rm{ln}}\;{\rm{cRNA2}} \times \beta {\rm{ln}}\;{\rm{cRNA2}} + \ldots {\rm{exp}}\;{\rm{ln}}\;{\rm{cRNAn}} \cr & \quad \times \beta {\rm{ln}}\;{\rm{cRNAn}}}$$\end{document}$$(where "exp" is the expression level of DElncRNAs, and "β" is the regression coefficient obtained from the multivariate Cox analysis), and we plotted the results using the survminer package of R software. LUSC patients were divided into high-risk group and low-risk group with a median risk score as the threshold. The survival receiver operating characteristic (ROC) package was used to map the ROC curve to explore the sensitivity of the 3-year survival rate of DElncRNAs to LUSC patients.

Results
=======

Identification and screening of differentially expressed RNAs
-------------------------------------------------------------

Datasets on 551 samples (502 tumor, 49 normal) of lncRNA and mRNA and 523 miRNA samples (478 tumor, 45 normal) were retrieved from the TCGA database. Analysis of the normal and LUSC samples identified 170 DElncRNAs (95 down-regulated, 75 up-regulated), 331 DEmiRNAs (91 down-regulated, 240 up-regulated), and 417 DEmRNAs (109 down-regulated, 308 up-regulated) differentially expressed RNAs. Volcano plots visually demonstrating the distribution of DElncRNAs, DEmiRNAs and DEmRNAs are shown in [Fig. 1](#fig-1){ref-type="fig"}.

![Volcano plots of differentially expressed RNAs (A, DElncRNAs; B, DEmiRNAs; C, DEmRNAs) in lung squamous cell carcinoma (LUSC).\
Pink dot represents the up-regulated differential expression of the RNA, gray dot represents the down-regulated differential expression of the RNA, black spot represents the indifferentially expressed RNA.](peerj-07-7727-g001){#fig-1}

Construction of the ceRNA network
---------------------------------

Elements from the differentially expressed RNAs were adopted to construct the ceRNA network of lncRNA-miRNA-mRNA. Since MREs are the mediators of lncRNA-miRNA interaction, we utilized the miRcode online website to identify relationships between the 170 DElncRNAs and 331 DEmiRNAs. The interactions between the DEmiRNAs and 417 DEmRNAs were then assessed using StarBase and TargetScanHuman, and the target genes of the miRNAs were predicted. After processing the collected data, we identified the connections between DElncRNAs, DEmiRNAs and DEmRNAs in the ceRNA network. The lncRNA-miRNA-mRNA ceRNA network consisted of 27 lncRNAs (13 down-regulated, 14 up-regulated, [Table 1](#table-1){ref-type="table"}), 43 miRNAs (14 down-regulated, 29 up-regulated, [Table 2](#table-2){ref-type="table"}) and 11 mRNAs (two down-regulated, nine up-regulated, [Table 3](#table-3){ref-type="table"}) which was visualized with the Cytoscape software package, as that shown in [Fig. 2](#fig-2){ref-type="fig"}.

![The lncRNA-miRNA-mRNA competitive endogenous (ceRNA) network.\
Diamonds represent lncRNAs, rectangles represent miRNAs, and circles represent mRNAs; Red, up-regulation; blue, down regulation.](peerj-07-7727-g002){#fig-2}
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###### lncRNAs in ceRNA network of LUSC.

![](peerj-07-7727-g008)

  lncRNA        logFC          *P*-value     FDR
  ------------- -------------- ------------- -------------
  AC022148.1    −1.22769209    1.53E-05      0.001458804
  AC078802.1    −1.188321037   6.05E-11      1.8E-08
  LINC00308     −1.691498698   0.000108666   0.00608259
  AF241725.1    −3.618368756   1.09E-10      3.06E-08
  MUC2          2.717963118    3.06E-05      0.002499606
  TDRG1         2.517216708    0.00020126    0.009470266
  HCG9          1.109283012    9.7E-06       0.001046319
  C12orf77      2.589970135    3.01E-05      0.002499606
  LINC00348     −2.134854747   8.76E-08      1.43E-05
  LINC00200     4.214062982    2.27E-05      0.002016136
  LINC00452     −3.818163377   3.46E-55      1.03E-51
  LINC00379     −4.237133444   2.36E-16      1.32E-13
  DSCR9         −1.904132736   1.57E-28      1.4E-25
  TTTY20        5.32296051     4.67E-05      0.003388398
  ERVH48-1      2.050090632    7.75E-05      0.004922008
  OSTN-AS1      −2.176258452   2.11E-15      1.05E-12
  LINC00460     −1.236654671   9.96E-05      0.005680506
  DSCAM-AS1     3.729458571    3.66E-05      0.002847536
  SEC62-AS1     −1.10916205    2.89E-11      9.58E-09
  AP003108.1    2.335384343    0.000111817   0.006181707
  AC006111.2    −1.003635081   3.81E-10      9.75E-08
  PEX5L-AS1     4.973540045    3.3E-05       0.002637378
  AC011453.1    2.269153018    0.000189415   0.009160309
  AL139147.1    −1.560450349   5.56E-11      1.72E-08
  C5orf17       2.6306622      3.53E-05      0.002772444
  CACNA1C-AS2   1.036243554    4.26E-05      0.003153043
  LINC00261     1.826424051    0.000184699   0.008990016

10.7717/peerj.7727/table-2

###### miRNAs in ceRNA network of LUSC.

![](peerj-07-7727-g009)

  miRNA          logFC          *P*-value      FDR
  -------------- -------------- -------------- --------------
  hsa-mir-106a   1.204542323    1.79324E-08    5.07705E-08
  hsa-mir-372    7.211115986    1.77878E-07    4.6798E-07
  hsa-mir-373    5.491263047    5.57042E-06    1.16791E-05
  hsa-mir-140    −2.145012335   1.53063E-88    7.90041E-87
  hsa-mir-144    −3.596239815   1.48485E-120   1.42334E-118
  hsa-mir-145    −1.523223033   1.10263E-47    1.84966E-46
  hsa-mir-195    −1.989967259   4.44425E-89    2.48508E-87
  hsa-mir-424    1.314733704    3.32903E-17    1.70517E-16
  hsa-mir-497    −1.773975357   2.21392E-73    8.25299E-72
  hsa-mir-519d   2.74891462     0.000453143    0.000732672
  hsa-mir-193b   1.678689637    1.14722E-16    5.66018E-16
  hsa-mir-204    1.240774752    0.002222996    0.003242675
  hsa-mir-205    5.590239194    1.11276E-66    3.24635E-65
  hsa-mir-508    1.153563579    0.004202669    0.005862767
  hsa-mir-31     5.2212886      1.51878E-28    1.49868E-27
  hsa-mir-96     2.685751917    1.04143E-38    1.3702E-37
  hsa-mir-507    1.778592543    0.001555683    0.002340501
  hsa-mir-137    2.7927536      3.21271E-07    8.29126E-07
  hsa-mir-150    −1.11711056    4.26164E-11    1.52918E-10
  hsa-mir-182    1.939944519    6.04088E-26    5.13093E-25
  hsa-mir-107    −1.021389186   1.01701E-38    1.36483E-37
  hsa-mir-141    1.613009544    2.58646E-28    2.47931E-27
  hsa-mir-200a   1.397198311    3.14653E-19    1.84878E-18
  hsa-mir-338    −2.653720029   1.7246E-76     7.71471E-75
  hsa-mir-503    2.067221998    3.92717E-23    2.89575E-22
  hsa-mir-143    −1.855474343   1.58774E-56    3.43669E-55
  hsa-mir-183    2.684152732    5.5481E-44     8.09299E-43
  hsa-mir-184    1.541248557    0.006683239    0.009096255
  hsa-mir-192    1.189417464    1.08144E-06    2.5551E-06
  hsa-mir-429    1.282775787    3.14783E-13    1.29582E-12
  hsa-mir-210    4.222814074    6.21437E-78    2.97846E-76
  hsa-mir-122    5.475024505    6.36543E-06    1.32235E-05
  hsa-mir-383    3.23391922     1.6056E-05     3.18745E-05
  hsa-mir-206    −2.567004308   5.95329E-10    1.92051E-09
  hsa-mir-506    1.554323985    0.002916241    0.004136993
  hsa-mir-187    1.212237918    9.54276E-05    0.000169846
  hsa-mir-301b   3.430526866    6.74228E-36    8.22558E-35
  hsa-mir-223    −1.420618542   1.61845E-17    8.61887E-17
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###### mRNAs in ceRNA network of LUSC.

![](peerj-07-7727-g010)

  mRNA     logFC          *P*-value     FDR
  -------- -------------- ------------- -------------
  FGF9     1.61326903     2.26333E-06   0.000252016
  LIN28A   2.797827119    6.13483E-06   0.00055381
  DDC      2.334079077    7.64372E-06   0.000667239
  HEPHL1   −1.322084771   2.1341E-05    0.001451956
  ELAVL4   1.474052098    2.27E-05      0.001516243
  APOA5    2.500418268    3.44584E-05   0.002104578
  ZFHX4    −1.001356548   3.89705E-05   0.002318933
  PHOX2B   4.694250508    0.000148939   0.006179984
  HNF4A    1.652513288    0.00015419    0.006303464
  GSG1     1.653322746    0.000215112   0.008074781
  LEFTY2   1.32763658     0.000245332   0.008904518

Description of GO enrichment analysis
-------------------------------------

To clearly comprehend the biological functions of the DElncRNAs in LUSC patients, we analyzed the mRNAs of the ceRNA network and identified the GO terms regulated by the lncRNAs. GO functional enrichment analysis covers three biological aspects, molecular function (MF), biological process (BP) and cellular component (CC). Based on a *P*-value \< 0.05, the 11 mRNAs identified in our study played a major role in BP and MF, and four terms (triglyceride homeostasis, positive regulation of neuron differentiation, SMAD protein signal transduction, mRNA binding) were considered valuable. Similarly, the GO terms for all 417 DEmRNAs are also concentrated in BP and MF which cover the four GO terms of 11 mRNAs in the ceRNA network. Therefore, the differential RNA and ceRNA networks we identified in this study are of biological significance.

Verification of prognosis-related RNAs and construction of prognostic model
---------------------------------------------------------------------------

Three lncRNAs (ERVH48-1, HCG9, and SEC62-AS1) and 5 miRNAs (hsa-mir-223, hsa-mir-301b, hsa-mir-338, hsa-mir-383, and hsa-mir-424) were identified as being significantly associated with the overall survival of LUSC patients by Kaplan--Meier survival analysis and log-rank test (*P* \< 0.05). Among them, when the three lncRNAs (ERVH48-1, HCG9, and SEC62-AS1) and two miRNAs (hsa-mir-223, hsa-mir-338) were highly expressed, the prognosis of LUSC patients were poor also, the 1-year overall survival rate of patients with high expression of these three miRNAs (hsa-mir-301b, hsa-mir-383, hsa-mir-424) is higher than that of patients with low expression ([Figs. 3](#fig-3){ref-type="fig"} and [4](#fig-4){ref-type="fig"}). In addition, after filtration and calibration in the two tumor databases TCGA and GEO, four mRNAs (DDC, FGF9, GSG1, LEFTY2) were also identified as being associated with overall survival. When GSG1 was down-regulated and DDC, FGF9, and LEFTY2 were up-regulated, patients had a long survival period (red, high-expression; black, low-expression) ([Fig. 5](#fig-5){ref-type="fig"}). Furthermore, univariate Cox analysis identified six lncRNAs as meaningful ([Table 4](#table-4){ref-type="table"}), while only five lncRNAs (AC022148.1, HCG9, LINC00460, C5orf17, LINC00261) were still associated with prognosis in multivariate Cox analysis. And risk score analysis identified that the high-risk group had a worse prognosis than the low-risk group ([Fig. 6](#fig-6){ref-type="fig"}). Combining the results of Kaplan--Meier analysis with Cox analysis, we obtained seven prognostic-related lncRNAs (ERVH48-1, HCG9, SEC62-AS1, AC022148.1, LINC00460, C5orf17, LINC00261). It is worth noting that HCG9 is meaningful in both Kaplan--Meier analysis and Cox analysis. The ROC curve was consistent with the results of the multivariate analysis with the area under the curve of 3-year survival of 0.63, which indicated its utility as a prognostic model for predicting the survival status of LUSC ([Fig. 7](#fig-7){ref-type="fig"}).

![Survival curves for DElncRNAs that are associated with the overall survival (OS) of LUSC patients.\
(A) ERVH48-1, (B) HCG9, (C) SEC62-AS1.](peerj-07-7727-g003){#fig-3}

![Survival curves for DEmiRNAs that are associated with the overall survival (OS) of LUSC patients.\
(A) hsa-mir-223, (B) hsa-mir-301b, (C) hsa-mir-338, (D) hsa-mir-383, (E) hsa-mir-424.](peerj-07-7727-g004){#fig-4}

![Survival curves for DEmRNAs that are associated with the overall survival (OS) of LUSC patients.\
(A) DDC, (B) FGF9, (C) GSG1, (D) LEFTY2.](peerj-07-7727-g005){#fig-5}

![The result of multivariate Cox analysis.](peerj-07-7727-g006){#fig-6}

![The receiver operating characteristic (ROC) curve of the 3-year survival rate.](peerj-07-7727-g007){#fig-7}
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###### Significant lncRNAs in univariate Cox analysis.

![](peerj-07-7727-g011)

  Gene         HR            *P*-value     Regulate
  ------------ ------------- ------------- ----------
  LINC00261    1.075703271   0.008013221   up
  HCG9         1.152099121   0.028617889   up
  C5orf17      1.05908045    0.029548444   up
  LINC00460    1.060955462   0.038113165   down
  AC022148.1   1.089323602   0.047549964   down
  AC078802.1   0.893773288   0.048069161   down

Discussion
==========

Lung squamous cell carcinoma is a common form of lung cancer. Because of the lack of research on genomic alterations and other causes, there are still no molecularly targeted drugs that can specifically treat LUSC, and the number of deaths per year due to LUSC remains a concern ([@ref-6]; [@ref-15]). With the growing maturity of bioinformatics and high-throughput sequencing technology, the mysterious veil surrounding lncRNA has also begun to be removed ([@ref-4]; [@ref-32]). Studies have shown that lncRNAs were abnormally expressed in a variety of tumors, which can affect the occurrence, growth, metastasis and prognosis of tumors ([@ref-27]). In this study, we established a ceRNA network based on the expression matrices of lncRNA, miRNA, and mRNA. Furthermore, we explored the relationship between them and the overall survival of LUSC patients. Finally, we identified seven prognostic-related lncRNAs in LUSC based on the theoretical basis of the ceRNA network and on data from the TCGA database.

The ceRNA network constructs a novel regulatory model of lncRNA-miRNA-mRNA, which enriches the traditional miRNA-mRNA regulatory model. And the function of lncRNA will be better explained in ceRNA network. Among GO terms of mRNAs regulated by the lncRNAs, the function SMAD protein signal transduction deserves attention, which plays a major role in tumor progression and drug resistance ([@ref-16]; [@ref-53]), and each biological process in a tumor is basically associated with the pathway of mRNA binding ([@ref-10]; [@ref-33]). In the ceRNA network constructed in present study, five lncRNAs (AC022148.1, HCG9, LINC00460, C5orf17, LINC00261) were identified in the construction of LUSC prognostic model. HCG9, which was thought to be associated with susceptibility and heredity of nasopharyngeal carcinoma in other related studies ([@ref-41]; [@ref-52]). And in a related genomic study of Hodgkin's lymphoma, HCG9 was recognized to be associated with genetic variation ([@ref-40]). LINC00460 is important for the development or prognosis of a variety of cancers. In non-small cell lung cancer, LINC00460 acts as a cancer factor to promote the spread and metastasis of cancer cells ([@ref-26]). In a number of studies, it was identified as a prognostic marker of some cancers that can guide clinical practice, such as head and neck squamous cell carcinoma ([@ref-7]), epithelial ovarian cancer ([@ref-28]). After reviewing the relevant literature, we found that LNIC00261 plays a non-negligible role in the development and prognosis of cancer similarly. In the study of the regulation of lncRNA, LINC00261 is able to prevent the progression of gastric cancer by promoting the degradation of Slug ([@ref-47]). One study has shown that LINC00261 was differentially expressed in gastric cancer, which may provide a new target for the treatment of gastric cancer ([@ref-8]). AC022148.1 and C5orf17 are two newly discovered lncRNAs associated with LUSC prognosis in this study and no scholars have studied their role and mechanism in cancers. Therefore, we suggest that new research can be carried out around them.

In addition to constructing a lncRNA prognostic model, we also identified prognostic significance of lncRNAs by performing Kaplan--Meier survival curves and log-rank tests. As a result, three lncRNAs (ERVH48-1, HCG9, and SEC62-AS1) were identified as prognostic indicators associated with the overall survival of LUSC patients. ERVH48-1 is an endogenous retroviral provirus with placental-specific expression, which plays a role in tumor formation ([@ref-29]). SEC62-AS1 is an antisense RNA for SEC62, which can be used to treat diseases caused by genetic mutation or overexpression ([@ref-44]). Therefore, we have reason to believe that SEC62-AS1 may be a protective gene for tumors. Among them, HCG9 is meaningful in both survival analysis and Cox analysis, which strongly enhances the reliability of it as a prognostic indicator.

We also performed survival validation on miRNAs and mRNAs in the network to ensure the survival correlation of the entire ceRNA network. There were five miRNAs (hsa-mir-223, hsa-mir-301b, hsa-mir-338, hsa-mir-383, and hsa-mir-424) identified to be associated with the overall survival of LUSC patients. In related studies, the 5′ hat structure of hsa-mir-223 is associated with tumor metastasis in HPV-negative vulvar cancer ([@ref-13]). The expression profile of hsa-mir-301b is altered in lung adenocarcinoma, pancreatic cancer and papillary thyroid cancer ([@ref-1]; [@ref-19]; [@ref-46]). Hsa-mir-338 can indirectly regulate certain signal transduction pathways or directly target potential genes to regulate tumor cells' proliferation and invasion ([@ref-21]). Down-regulation or up-regulation of hsa-mir-383 expression is thought to affect cell cycle and synthesis of apoptotic proteins which is considered to be a tumor marker for a variety of tumors (some studies have regarded it as a prognostic marker for lung cancer) ([@ref-37]). Hsa-mir-424 was also inextricably linked to tumors, such as its 5′ hat structure which can inhibit the progression of gastric cancer ([@ref-49]), reduce chemotherapy resistance in breast cancer ([@ref-34]), and act as a radiation sensitizer for cervical cancer among other functions ([@ref-42]). In addition, four mRNAs (DDC, FGF9, GSG1, and LEFTY2) were considered to be significant for the overall survival of LUSC patients as verified by information from the GEO database. DDC, is a dopa deacidase, the expression of which is related to the biochemistry of many human cancers ([@ref-23]). Based on a number of previous studies, the expression of FGF9 showed carcinogenicity in human tumors ([@ref-22]). There are very few reports on GSG1 in terms of tumors, and most studies believe that it is involved in reproduction. And LEFTY2 was involved as a target gene in the development of some malignant tumors ([@ref-18]). From the above description, we believe that the three type of prognosis-related RNAs obtained in ceRNA network has a good tumor correlation.

In present study, we verified the accuracy of the information obtained from the TCGA database using data from the GEO database. Also, excluding undiscovered RNAs, there is a good tumor correlation in the identified survival-related RNAs in present study; what's more, a variety of analytical methods and software, such as Kaplan--Meier survival analysis, log-rank test, univariate Cox and multivariate Cox analysis and different R packages were utilized to improve the reliability of the data analysis. Our work has injected new energy into ceRNA network research related to lncRNAs in LUSC. It needs to be mentioned that we focus on finding the prognostic markers of LUSC in the cumbersome data of the tumor database. Therefore, our research remains at the theoretical level. Since our findings have not yet been applied in clinical work, more researches are needed in the future to validate our findings.

Conclusion
==========

As a conclusion, we separately used the two methods, survival verification and construction of prognostic model, identified the seven specific lncRNAs (ERVH48-1, HCG9, SEC62-AS1, AC022148.1, LINC00460, C5orf17, LINC00261) as potential prognostic factors for LUSC patients based on the ceRNA network theory. Five of the seven lncRNAs (AC022148.1, HCG9, LINC00460, C5orf17, LINC00261) constructed a prognostic model of LUSC, which may be used to assess the prognosis risk of clinical patients. Further biological experiments are needed to elucidate their specific molecular mechanisms.
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